CURRENT APPROACHES TO THERAPY TYPE 2 DIABETES - EFFECT ON INSULIN RESISTANCE


如何引用文章

全文:

详细

The article discusses main risk factors and mechanisms of development for type 2 diabetes mellitus (DM2) and its cardiovascular complications. Particular attention is paid to the pathogenetic relationship of metabolic disorders, insulin resistance and compensatory hyperinsulinemia that are fundamental for the development of DM2. In addition to drug-free methods for correction of disorders in DM2, treatment should include the drugs that increase tissue insulin sensitivity. Such drugs include primarily biguanides and thiazolidinediones (glitazones), whose effectiveness has been proven in large international placebo-controlled studies. Particular attention is paid to Amalvia (pioglitazone), modern drug for the treatment of DM2, which is used as a monotherapy and in combination with other oral hypoglycemic agents and/or insulin.

参考

  1. Wild S, Roglic G, et al. Global Prevalence of Diabetes. Estimates for the year 2000 and projections for 2030. Diab Care 2004;27:1047-53.
  2. Дедов И.И., Ремизов О.В., Петеркова В.А. Сахарный диабет второго типа у детей и подростков // Сахарный диабет 2001. № 4. C. 26-31.
  3. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diab 1988;37:1595-607.
  4. Чазова И.Е., Мычка В.Б. Метаболический синдром. М., 2004.
  5. D'Agostino R, Hamman R, Karter A, et al. Cardiovascular disease risk factors predict the development of type 2 diabetes. Diab Care 2004;27(9):2234-40.
  6. American Diabetic Association. Insulin resistance. Diabetes Care 1998;21:310-14.
  7. Balkau B, Eschwege E. Insulin resistance: an independent risk factor for cardiovascular disease. Diab Obesity Metab 1999;1(1):S23-31.
  8. Nigro J, Osman N, Dart A, et al. Insulin resistance and atherosclerosis. Endocrine Reviews 2006;27(3):242-59.
  9. Дедов И.И., Шестакова М.В. Сахарный диабет и артериальная гипертензия. М., 2006.
  10. Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Eng J Med 2007;14:356-40.
  11. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298(10):1180-88.
  12. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controled trial. Lancet 2005;366:1279-89.
  13. Hiralal R, Koo KK, Gerstein HC. Does pioglitazone prevent macrovascular events in patients with type 2 diabetes. CMAJ 2006;174(8):1090-91.
  14. Seare DD, Haiao A, Ofrecio JM, at al. Selective modulation of promoter recruitment and tranacriptional activity of PPARgamma. Bioch Bioph Rea Comun 2007;364:515-21.
  15. Xiang H, Peters RK, Kjos SL, et al. Effect of Pioglitazone on Pancreatic b-cell function and diabetes risk in hispanic Women With Prior Gestational Diabetes. Diab 2006;55(2):517-22.
  16. From Prediabetes to Diabetes to Cardiovascular Complications: Is the Progression Preventable? Medscape 2007.
  17. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. // N Engl J Med 2006;355: 297-307.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2011
##common.cookie##